Biomica CEO to Participate in Panel Discussion at 7th European Annual Microbiome Movement
01/24/2023 - 07:00 AM
REHOVOT, Israel , Jan. 24, 2023 Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced its CEO and VP R&D will both be participating in 7th Annual Microbiome Movement Drug Development Europe, taking place in London, UK , between January 31 and February 2 , 2023.
The 7th Microbiome Movement – Drug Development Summit Europe aims to unite Europe's leading drug developers and microbiome experts to share their latest discoveries on microbiome functionality, translation, clinical development, biomarker discovery and manufacturing scale-up. In attendance from Biomica will be CEO Dr. Elran Haber and VP R&D Dr. Shiri Meshner.
Dr. Haber will take part in two industry panel discussions. These are entitled, "How to Turn Outstanding Microbiome Science into Effective & Efficient Products ", taking place on February 1, 2023 , at 9:30am GMT and "Working with Microbiome Investors ", scheduled to take place later that day at 4:30pm GMT .
Dr. Meshner will be presenting on February 1, 2023 , at 2:55pm , and the presentation is entitled, "Rationally Designed LBPs – From Computational & Pre-clinical Data to Clinical Studies. "
Dr. Haber and Dr. Meshner will both be available for one-on-one meetings at the conference, and those interested should be in touch with the investor or public relations team.
About Biomica
Biomica is a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN). For more information, please visit www.biomicamed.com .
Logo - https://mma.prnewswire.com/media/1974949/Biomica.jpg https://mma.prnewswire.com/media/1947468/Evogene.jpg
Evogene Contacts: Kenny Green kenny.green@evogene.com
Public Relations: Lital Mamon lital.mamon@evogene.com
https://www.prnewswire.com/news-releases/biomica-ceo-to-participate-in-panel-discussion-at-7th-european-annual-microbiome-movement-301729122.html
SOURCE Biomica Ltd.
EVGN Rankings
#4065 Ranked by Stock Gains
EVGN Stock Data
Industry
Pesticide and Other Agricultural Chemical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology
About EVGN
evogene is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. the company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. in addition, evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. the company's headquarters are located in rehovot, israel and is listed for trading on the tel aviv stock exchange (tase: evgn) and on the new york stock exch
